These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31181537)

  • 1. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
    Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
    Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
    Cardarella S; Ogino A; Nishino M; Butaney M; Shen J; Lydon C; Yeap BY; Sholl LM; Johnson BE; Jänne PA
    Clin Cancer Res; 2013 Aug; 19(16):4532-40. PubMed ID: 23833300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
    Barlesi F; Mazieres J; Merlio JP; Debieuvre D; Mosser J; Lena H; Ouafik L; Besse B; Rouquette I; Westeel V; Escande F; Monnet I; Lemoine A; Veillon R; Blons H; Audigier-Valette C; Bringuier PP; Lamy R; Beau-Faller M; Pujol JL; Sabourin JC; Penault-Llorca F; Denis MG; Lantuejoul S; Morin F; Tran Q; Missy P; Langlais A; Milleron B; Cadranel J; Soria JC; Zalcman G;
    Lancet; 2016 Apr; 387(10026):1415-1426. PubMed ID: 26777916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with non-small-cell lung cancer harbouring a
    Auliac JB; Bayle S; Vergnenegre A; Le Caer H; Falchero L; Gervais R; Doubre H; Vinas F; Marin B; Chouaid C
    Curr Oncol; 2018 Oct; 25(5):e398-e402. PubMed ID: 30464690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
    Yamaguchi T; Shimizu J; Matsuzawa R; Watanabe N; Horio Y; Fujiwara Y
    BMC Cancer; 2024 Jul; 24(1):842. PubMed ID: 39009968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting
    Baik CS; Myall NJ; Wakelee HA
    Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
    Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
    Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
    Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;
    Cancer Treat Rev; 2022 Feb; 103():102335. PubMed ID: 35033867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
    Wiesweg M; Preuß C; Roeper J; Metzenmacher M; Eberhardt W; Stropiep U; Wedeken K; Reis H; Herold T; Darwiche K; Aigner C; Stuschke M; Schildhaus HU; Schmid KW; Falk M; Heukamp L; Tiemann M; Griesinger F; Schuler M
    Eur J Cancer; 2021 May; 149():211-221. PubMed ID: 33872981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
    Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
    J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
    Hamard C; Ruppert AM; Lavole A; Rozensztajn N; Antoine M; Cadranel J; Wislez M
    Ann Pathol; 2016 Jan; 36(1):63-72. PubMed ID: 26775573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
    Myall NJ; Henry S; Wood D; Neal JW; Han SS; Padda SK; Wakelee HA
    Clin Lung Cancer; 2019 Mar; 20(2):e208-e217. PubMed ID: 30442523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
    Wu H; Feng J; Lu S; Huang J
    Cancer Med; 2024 May; 13(10):e7305. PubMed ID: 38770647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].
    Liu X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
    Blons H; Oudart JB; Merlio JP; Debieuvre D; de Fraipont F; Audigier-Valette C; Escande F; Hominal S; Bringuier PP; Fraboulet-Moreau S; Ouafik L; Moro-Sibilot D; Lemoine A; Langlais A; Missy P; Morin F; Souquet PJ; Barlesi F; Cadranel J; Beau-Faller M;
    Lung Cancer; 2021 Jan; 151():69-75. PubMed ID: 33248711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
    Beau-Faller M; Texier M; Blons H; Richard N; Escande F; Melaabi S; Lizard S; De Fraipont F; Longchampt E; Morin F; Zalcman G; Pignon JP; Cadranel J
    Clin Lung Cancer; 2019 May; 20(3):222-230. PubMed ID: 30679079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.